Hangzhou Biotest Biotech Co.,Ltd.
Shanghai Stock Exchange 688767.SS
Hangzhou Biotest Biotech Co.,Ltd. Current Liabilities for the year ending December 31, 2023: USD 21.05 M
-
Hangzhou Biotest Biotech Co.,Ltd. Current Liabilities for the year ending December 31, 2022 was USD 24.79 M, a -50.40% change year over year.
-
Hangzhou Biotest Biotech Co.,Ltd. Current Liabilities for the year ending December 31, 2021 was USD 49.98 M, a 71.17% change year over year.
-
Hangzhou Biotest Biotech Co.,Ltd. Current Liabilities for the year ending December 31, 2020 was USD 29.20 M, a 182.37% change year over year.
-
Hangzhou Biotest Biotech Co.,Ltd. Current Liabilities for the year ending December 31, 2019 was USD 10.34 M, a 27.33% change year over year.
| Date | Current Liabilities | Total Non-Current Liabilities | Shareholders' Equity | Long-Term Debt |
|---|
Don’t Miss A Beat
| CEO | Mr. Shujiang Wu |
| IPO Date | Sept. 8, 2021 |
| Location | China |
| Headquarters | No.17, Futai Road |
| Employees | 629 |
| Sector | Healthcare |
| Industries | |
Hangzhou Biotest Biotech Co., LTD. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and equipment in China and Internationally. It offers medical test products for fertility health, oncology, cardiology, inflammation, biochemistry, and various infectious diseases, as well as COVID-19 rapid tests, such as antibody and antigen testing kits; and urine and saliva drug, hair drug, and vitamin D rapid testing kits. The company also provides immunochromatography readers and fluorescence immunoassay quantitative analyzers. Hangzhou Biotest Biotech Co., LTD. was founded in 2008 and is based in Hangzhou, China.
Past 5 years
StockViz Staff
February 2, 2025
Any question? Send us an email